CAR-T in Relapsed/Refractory Multiple Myeloma

The treatment options for multiple myeloma have evolved significantly over the years, providing patients with a range of therapies tailored to their specific circumstances. The choice of treatment often hinges on various factors, including the aggressiveness of the disease, individual prognostic indicators like genetic markers, the overall physical condition of the patient, and any pre-existing health issues that may affect treatment decisions. Current therapeutic strategies include several classes of drugs, each working through different mechanisms. Proteasome inhibitors (PIs) disrupt the pro

Trial Details

NCT ID
NCT07689058
Phase
PHASE2
Sponsor
Dr. Zaineb Akram
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • CAR-T
Locations (sample)
  • Rawalpindi, Punjab Province, Pakistan|33.59733,73.0479
  • Rawalpindi, Punjab Province, Pakistan|33.59733,73.0479

Key Eligibility Criteria

  • Male and female participants of age 18 years and above.
  • Patients with a confirmed diagnosis of multiple myeloma according to IMWG diagnostic criteria.
  • Received at least 3 prior multiple myeloma treatment lines of therapy or are double refractory to an IMiD and PI (refractory multiple myeloma as de…
  • Measurable disease at Screening as per IMWG criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →